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Abstract
PTEN (Phosphatase and tensin homolog) is a tumour suppressor gene commonly defective in human cancer, and is thus a
potentially important therapeutic target. Targeting tumour suppressor loss-of-function is possible by exploiting the genetic
concept of synthetic lethality (SL). By combining the use of isogenic models of PTEN deficiency with high-throughput RNA
interference (RNAi) screening, we have identified Nemo-Like Kinase (NLK) inhibition as being synthetically lethal with PTEN
deficiency. This SL is likely mediated by the transcription factor FOXO1 (Forkhead box O1), an NLK substrate, as the
selectivity of NLK gene silencing for PTEN deficient cells can be reversed by FOXO1 knockdown. In addition, we provide
evidence that PTEN defective cells targeted by NLK gene depletion undergo senescence, suggesting that NLK function is
critical for the continued proliferation of PTEN deficient cells. Taken together, these data provide new insight into the
potential of targeting of NLK to treat a range of tumourigenic conditions characterised by PTEN deficiency.
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Introduction
Loss of function mutations in the tumour suppressor gene PTEN
or lack of PTEN expression have both been observed in a wide
range of human tumours [1]. PTEN encodes a phosphatase whose
activity antagonises PI3 kinase signaling by dephosphorylating the
plasma membrane lipid phosphoinositide-3,4,5-trisphosphate
(PIP3). The loss of PTEN phosphatase activity is thought to foster
tumourigenesis, at least in part, by causing downstream constitu-
tive activation of AKT. In addition to this role, PTEN has been
suggested to have a nuclear function in maintaining genomic
stability [2].
The presence of tumour-specific loss-of-function mutations in
PTEN raises the possibility of identifying PTEN synthetic lethal
interactions that could be exploited therapeutically. Previously, we
have shown that PTEN deficiency is synthetically lethal with
inhibition of PARP1 [3], and effect predicted from the proposed
role of PTEN in maintaining genomic stability [2]. It is likely that
additional SLs involving PTEN exist, and these might prove
valuable candidate therapeutic approaches. High-throughput
genetic screening using RNA interference (RNAi) represents a
straightforward method to identifying SLs in a relatively unbiased
fashion [4].
Results and Discussion
We used a high-throughput screening (HTS) approach to
identify novel SLs involving PTEN (Figure 1A). Specifically, we
reverse-transfected PTEN wild type and null human tumour cell
lines with a short-interfering (si)RNA library arrayed in 96-well
plates and measured effects of each siRNA on cell proliferation
using CellTiter-GloH reagent (Promega) five days after transfec-
tion. The siRNA library we used comprised 779 siRNA SMART-
pools (Dharmacon), each designed to target a specific kinase or
kinase-related gene. We selected this gene subset to screen given its
inherent pharmacological tractability. To maximise the possibility
of identifying SLs specific to PTEN, we carried out triplicate
screens in a pair of isogenically matched HCT116-derived wild-
type (PTEN+/+) and PTEN2/2 colorectal tumour cell lines [5].
PTEN deficiency in this model was achieved by targeting a
truncating mutation to both copies of PTEN at exon 2, with the
resultant mutant alleles encoding an ostensibly dysfunctional
PTEN mutant protein consisting of only the 24 N-terminal amino-
acids [6,7].
The sensitivity of the screen and its overall performance were
monitored through a series of commonly used HTS metrics [8].
These included: (i) PLK1 siRNA causing a reduction in viability of
more than 90% in both cell types, when compared to transfection
with a non-targeting siRNA control (siCON); (ii) Z9-factor
estimation between negative (siCON) and positive (siPLK1)
control wells where a Z9$0.5 was set as a threshold of acceptable
dynamic range (Figure S1); and (iii) ,10% inhibition in cell
proliferation caused by control non-targeting siRNA compared to
mock transfected wells. Transfected cell numbers were titrated to
ensure equal transfection efficiency and confluency in PTEN null
and wild-type cells. Following screen optimisation, each cell line
was screened three times and the data from replica screens
combined in the final analysis (Figure 1B).
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To identify PTEN selective effects we first calculated NPI
(normalised percent inhibition) scores [9] for each siRNA pool in
both PTEN+/+ and PTEN2/2 cell lines. To calculate NPI scores,
which scale cell viability effects according to maximal and minimal
effects, we defined the maximal inhibitory effect as that caused by
siRNAs targeting PLK1 and the minimal effect as that caused by
non-targeting control siRNAs. This procedure equalised data
distributions between both lineages, allowing the comparison of
NPI scores between PTEN2/2 and PTEN+/+ cells. This ultimately
allowed each siRNA pool to be ranked ordered according to its
PTEN2/2 selective effect.
We selected the 20 greatest PTEN2/2 selective effects (Table
S1) for technical validation using the original screening protocol in
a lower-throughput format to minimise false positive effects. This
analysis highlighted three genes with clear PTEN selective effects:
NLK (Nemo-Like Kinase), PLK4 (Polo-Like Kinase 4), and TTK (MPS1,
MonoPolar Spindle 1) (Figure 1C). Recently, we have used functional
viability profiling in non-isogenic breast tumour cell line models to
identify candidate SL effects, an analysis that identified TTK as
synthetically lethal with PTEN [10]. The identification of the
PTEN/TTK SL in the screen described here indicated that the
HTS performed on the isogenic models was able to identify bona
fide effects. The NLK, PLK4 and TTK effects were then subject to
further revalidation to exclude possible RNAi off-target effects.
Given that a phenotype caused by two distinct siRNA species
suggests a lower likelihood of an off-target effect [11], we reassayed
viability effects using each of the four different siRNA species that
comprise the SMARTpools used in the primary screen. Analysis
using these ‘‘deconvoluted’’ pools resulted in the identification of
at least two siRNAs for each gene that reproduced the original
effects (Figure 1C), In addition, the ability of these individual
siRNAs to silence their target genes was confirmed by immuno-
blotting (Figure 1D).
Highly penetrant ‘‘hard’’ SLs that are relatively unaffected by
additional genetic modifications are preferred over those that are
readily abrogated by other changes in the genetic background of a
cell. It seems likely that such hard synthetic lethalities are more
likely to be robust in genetically heterogeneous tumours [12]. To
address this issue, we used two additional isogenic models of
PTEN deficiency derived from (i) HEC1A endometrial and (ii)
DLD1 colorectal tumour cell lines. In both HEC1A and DLD1
models, homozygous mutation of PTEN was achieved using the
same targeting strategy as for the HCT116 models, where
truncating mutations were introduced into both copies of PTEN
Figure 1. PTEN synthetic lethality screening. (A) High-throughput screen (HTS) schematic. PTEN proficient and deficient HCT116 cells (Horizon
Discovery) were siRNA screened as described in the Methods. Example heatmaps from luminescence measurements in 96 well plates are shown. For
screening, a siGENOME SMARTPool library (Dharmacon) targeting 779 kinases and kinase-related genes was used. (B) Results from data analysis of
combined triplicate screens, represented as a scatter plot of Normalised Percent Inhibition (NPI) values from HCT116 PTEN2/2 and HCT116 PTEN+/+
screens. Blue dots corresponded to siPLK effects and red dots corresponded to siCON negative control effects. NPI values below the trend line shown
were considered as candidate synthetic lethalities. (C) Validation of PTEN synthetic lethal hits from the HTS using multiple siRNAs for each gene. Cells
were transfected with siRNA as per the HTS and surviving fractions calculated from CellTiterGlo luminescence measurements five days later. Surviving
fraction data from HCT116 PTEN2/2 and HCT116 PTEN+/+ cells transfected with each siRNA are shown. (D) Western blot showing silencing effects of
each siRNA.
doi:10.1371/journal.pone.0047249.g001
PTEN Synthetic Lethality with NLK
PLOS ONE | www.plosone.org 2 October 2012 | Volume 7 | Issue 10 | e47249
exon 2. Both, NLK and PLK4 SLs re-validated in the HEC1A
model, whilst the PTEN/PLK4 SL failed to re-validate in the
DLD1 isogenic matched pair (Figure 2A), possibly due to reduced
basal levels of PLK4 in DLD1 cells (Figure 2B). Although the
PTEN/PLK4 SL seemed not as prevalent as the PTEN/NLK SL,
it is possible that in some PTEN null cell types, PLK4 inhibition
exploits the underlying centromeric dysfunction of PTEN mutant
tumor cells. Aneuploidy is frequently observed in both human
breast carcinomas with low expression of PTEN and prostatic
intraepithelial neoplasia from Pten mutant mice. As PLK4 is
required for normal spindle function, controlled mitotic exit and
the suppression of chromosomal aneuploidy, it is possible that
PLK4 inhibition further exacerbates aneuploidy in PTEN null
cells and ultimately drives cell death.
To further assess the generality of our observations, we
examined NLK and PLK4 SLs in a wide panel of genetically
heterogenous PTEN deficient or proficient tumour cell lines
(Table 1). Here we used a combination of two validated siRNAs to
target each gene, alongside appropriate positive (siPLK1) and
negative (siCON) controls (Figure S2). Silencing of either NLK or
PLK4, had a greater cell inhibitory effect in the PTEN deficient
cohort when compared to the PTEN proficient group (Figure 2C,
2D), an effect especially evident for NLK silencing. Nevertheless,
the extent of the PTEN/NLK SL did vary across the cell line
panel and it seems possible that other genetic differences between
tumour cell models modulate the penetrance of the PTEN/NLK
SL.
Given the generality of the NLK/PTEN SL, we went on to
investigate the mechanism of NLK action in the context of PTEN
deficiency. Opposing the pro-oncogenic effects of PTEN dysfunc-
tion are molecular networks that normally promote quiescence,
senescence or cell death. These include the Forkhead O-class
transcription factors such as FOXO1 (‘Forkhead-box-O1’ iso-
form). In the face of PTEN deficiency, FOXO1 can exert tumour
suppressive effects by mediating the transcription of genes such as
p21, p27, and BIM that promote quiescence, senescence or cell
death. However, this tumour suppressive function of FOXO1 can
in turn be circumvented by the AKT activation that characterises
PTEN deficiency. The phosphorylation of FOXO1 by activated
AKT causes FOXO1 to be excluded from the nucleus and
ultimately degraded in the cytoplasm, minimizing its ability to
drive a tumour suppressive transcriptional programme [13].
Figure 2. Validation of the PTEN/NLK synthetic lethality. (A) Validation of PTEN synthetic lethal hits in additional isogenic models. Isogenic
HCT116, DLD1 and HEC1A PTEN proficient and deficient models were transfected with siRNA as in Figure 1 and surviving fractions calculated five
days later. Surviving fraction data from HCT116, HEC1A and DLD1 models is shown. * p value,0.05 Student’s t test (B) Western blot showing
expression of each candidate gene in three PTEN isogenic models. (C) Cell inhibitory effect of siRNA targeting NLK or PLK4 in a panel of 24 human
tumour cell lines (11 PTEN proficient models and 13 PTEN deficient models – see Table 1). (D) Box plots illustrating surviving fraction data for PTEN
proficient and deficient groups shown in (C). p-values were calculated with Student’s t-test.
doi:10.1371/journal.pone.0047249.g002
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One of the established functions of NLK is the AKT-
independent phosphorylation of FOXO1; this phosphorylation
also causes FOXO1 inactivation via its nuclear exclusion [14]. We
hypothesised that NLK inhibition could be synthetically lethal
with PTEN deficiency as it causes reactivation of FOXO1 and
therefore cellular senescence. To test if the PTEN/NLK synthetic
lethality was FOXO1 dependent, we transfected PTEN null cells
with both NLK and FOXO1 siRNA and assessed the effect on cell
inhibition. Whilst FOXO1 siRNA alone did not selectively target
PTEN null cells and NLK1 siRNA caused PTEN synthetic
lethality (as before), FOXO1 siRNA reversed the PTEN/NLK
synthetic lethality (Figure 3A, Figure S3), supporting the hypoth-
esis that the PTEN/NLK SL is FOXO1 dependent. NLK
silencing also caused an increase in nuclear FOXO1 localisation
(Figure 3B), again supporting the hypothesis. Furthermore, NLK
silencing induced senescence in PTEN deficient cells when
compared to PTEN proficient counterparts (Figure 3C, 3D),
suggesting that the instigation of a senescent programme by
FOXO1 could explain the PTEN/NLK synthetic lethality.
Our study demonstrates that NLK silencing inhibits PTEN
deficient tumour cells. Our mechanistic dissection of this effect
suggests that re-instatement of a FOXO1-driven process, possibly
cellular senescence that normally suppresses oncogenesis, could
explain the PTEN selective effect of NLK inhibition. As a
potential route to identifying leads for cancer drug discovery,
others have already identified compounds that cause the
translocation FOXO1 to the nucleus [15,16]. The data presented
here suggests that inhibition of NLK could provide a similar target
for drug development and the generation of toolbox small
molecule NLK inhibitors would allow proof of concept studies
to be performed including an in vivo assessment of the PTEN/NLK
SL. Ultimately, PTEN deficiency could be used as a biomarker to
identify patients likely to respond to a clinical NLK inhibitor.
Methods
PTEN synthetic lethality screening
PTEN proficient and deficient HCT116 cells (Horizon Discovery)
were maintained in McCoy’s 5A (Invitrogen) supplemented with
10% (v/v) foetal calf serum (FBS), glutamine and antibiotics and
reverse transfected with a siRNA library (final siRNA concentration
per well, 50 nM) using RNAiMAX (Invitrogen). For screening, a
siGENOME SMARTPool library (Dharmacon) targeting 779
kinases and kinase-related genes was used. The following day media
was changed and cells cultured for five subsequent days, at which
point cell viability was assessed using CellTiterGlo Luminescent Cell
Viability Assay (Promega). For validation experiments, cells were
transfected with siRNA as per the HTS and surviving fractions
calculated from CellTiterGlo luminescence measurements five days
later. All other cell lines were sourced from ATCC and maintained
as per the supplier’s instructions.
Western blots
Cells were transfected with siRNA and cell lysates generated
48 hours later. Whole-cell protein extracts were prepared from
cells lysed with RIPA buffer (Upstate) supplemented with protease
inhibitor cocktail tablets (Roche). Protein concentrations were
measured using Bio-rad Protein Assay Reagent. For western blot
analysis, lysates were electrophoresed on Novex 4–12% gradient
bis-tris pre-cast gels (Invitrogen) and immunoblotted overnight at
4uC with antibodies targeting the following epitopes: NLK (C-20:
sc-8210, Santa Cruz Biotechnology), PLK4 (#3258, Cell Signal-
ing), TTK (C-19: sc-540, Santa Cruz Biotechnology) and b-Actin
(I19: sc-1616, Santa Cruz Biotechnology). Incubation with
primary antibody was followed by incubation with a horseradish
peroxidase-conjugated secondary antibody and chemi-luminescent
detection of proteins (Amersham Pharmacia).
FOXO1 detection
HCT116 isogenic cells were co-transfected with GFP-tagged
FOXO1 cDNA (Origene) in addition to control (non targeting)
siRNA (siCON) or NLK siRNA. Two days later cells were fixed in
4% (w/v) para-formaldehyde, after which nuclei were stained with
49,6-diamidino-2-phenylindole (DAPI; D21490, Invitrogen). DAPI
and GFP signals from cells were captured using an inverted
confocal Zeiss LSM710 microscope.
Assessment of senescence
HCT116-derived PTEN isogenic cell lines were reversed
transfected with a pool of two validated siRNAs against NLK, as
well as siCON pool#2 (Dharmacon) as non-targeting control,
using RNAiMAX (Invitrogen). Seven days after transfection cells
were fixed in PBS containing 2% (w/v) formaldehyde and 0.2%
(v/v) glutaraldehyde, rinsed and incubated overnight at 37uC in a
solution containing X-gal according to manufacturer instructions
(Senescence b-Galactosidase Staining Kit, Cell Signaling Tech-
nology). After aspirating staining solution, cells were overlaid with
70% (v/v) glycerol and stored at 4uC until reading absorbance at
595 nm (A595) in a Victor X5 plate reader (Perkin Elmer). A595
Table 1. List of 24 cell lines, categorised as PTEN proficient
(n = 11) or deficient (n = 13) as defined by western blotting.
Cell line Origin
PTEN proficient models
MDA-MB-231 Breast
MDA-MB-361 Breast
MCF7 Breast
MCF10A Breast
MCF12A Breast
T47D Breast
A549 Lung
NCI-H226 Lung
PNT2 Prostate
DU145 Prostate
SW480 Colon
PTEN deficient models
MDA-MB-453 Breast
MDA-MB-468 Breast
SUM149 Breast
HCC70 Breast
CAL51 Breast
BT549 Breast
COLO-829 Melanoma
RPMI-7951 Melanoma
PC3 Prostate
LNCaP Prostate
UM-UC3 Bladder
H1650 Lung
A2780 Ovary
doi:10.1371/journal.pone.0047249.t001
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values were normalised to the A595 signal in PTEN proficient cells
transfected with siCONpool#2 transfected cells to give relative
senescence levels in each experimental sample.
Supporting Information
Figure S1 siRNA Screening Quality-Metrics. (A) Quality
control (QC) illustrating behavior of controls, with respective Z9-
factors, for a representative screen replicate covering the ten 96-
well plates covering the siRNA library. (B) Boxplots showing
distribution of the cell inhibitory effects of 779 siRNAs, averaged
from three screen replicates, for both PTEN deficient and
proficient HCT116-derived lineages. ‘‘Neg’’ represents the effect
of non-targeting control siRNA and ‘‘pos’’ the effect of siRNA
targeting PLK1. Negative Z scores represent cell inhibitory effects.
(PDF)
Figure S2 Evaluation of control siRNAs (siCON and siPLK1)
viability effects in a panel of 24 tumour cell lines. ‘‘Deficient’’ and
‘‘Proficient’’ indicate PTEN status.
(PDF)
Figure S3 Confirmation of silencing by FOXO1 and SKP2
siRNAs in HCT116 cells. Antibodies targeting epitopes of
FOXO1 (C29H4, cell signaling #2880) and SKP2 (cell signaling
#4358) were used for immuno-blotting.
(PDF)
Table S1 List of synthetic candidate hits from siKinome isogenic
screen highlighting Nemo-like kinase (NLK) results.
(PDF)
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Figure 3. PTEN/NLK synthetic lethality is abrogated by FOXO1 silencing. (A) Survival analysis of HCT116 cells transfected with NLK and/or
FOXO1 siRNA. HCT116 PTEN2/2 and HCT116 PTEN+/+ cells were transfected with siRNA targeting NLK and FOXO1 as shown and surviving fractions
determined after five days. The p value (*) was calculated using Student’s t test. (B) Nuclear localisation of FOXO1 is enhanced in PTEN deficient cells
upon NLK silencing. HCT116 isogenic cells were co-transfected with GFP-tagged FOXO1 cDNA in addition to control (non targeting) siRNA (siCON) or
NLK siRNA. Two days later cells were fixed and stained with DAPI. Green signal represents GFP-FOXO1 and blue signal represents nuclear DAPI
(nuclear) staining. Arrows indicate cells with nuclear localisation of FOXO1. (C) Senescence is increased by NLK siRNA in PTEN deficient cells. Bar chart
of relative relative senescence levels caused by NLK silencing are shown. HCT116-derived PTEN isogenic cell lines were reversed transfected with a
pool of two validated siRNAs against NLK, as well as siCON pool#2 (Dharmacon) as non-targeting control, using RNAiMAX (Invitrogen). Seven days
after transfection cells were fixed and incubated overnight at 37uC in a solution containing X-gal. (D) Representative images for b-Galactosidase
staining of PTEN deficient cells. Blue staining indicates b-Galactosidase.
doi:10.1371/journal.pone.0047249.g003
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